China Medical System Holdings Ltd. プレスリリース一覧


China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 23:06 JST

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Apr 01, 2024 21:30 JST

China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
Mar 28, 2024 11:29 JST

China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
Feb 04, 2024 10:00 JST

CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
Jan 02, 2024 15:00 JST

China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
Dec 13, 2023 18:36 JST

China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
Aug 24, 2023 21:00 JST

China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Jul 31, 2023 21:00 JST
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..

China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
Jun 12, 2023 21:00 JST

China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
May 30, 2023 23:00 JST
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..

CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy
Aug 26, 2022 19:00 JST

新着プレスリリース


もっと見る >>